Nagpur
08042755301
+919970006978

Erdanat-4 4 mg Tablets – Erdafitinib | Targeted Anticancer Medicine

Product Overview

Erdanat-4 is a prescription anticancer medicine containing Erdafitinib 4 mg, marketed by Natco Pharma. It belongs to a class of targeted cancer medicines known as FGFR inhibitors. It is used to treat certain patients with locally advanced or metastatic urothelial carcinoma (bladder cancer) when specific FGFR genetic alterations are present.

What Is Erdanat-4 4 mg?

Erdanat-4 contains Erdafitinib, a targeted therapy that works by blocking fibroblast growth factor receptors (FGFRs). These receptors can contribute to the growth and spread of certain cancer cells when they carry specific genetic alterations.

Treatment is selected based on the patient's cancer type and confirmed FGFR alteration status.

Product details:

  • Brand name: Erdanat-4

  • Composition: Erdafitinib 4 mg

  • Dosage form: Tablets

  • Manufacturer: Natco Pharma

  • Pack size: 28 tablets

  • Route of administration: Oral

  • Category: Targeted anticancer medicine / FGFR inhibitor

Uses and Benefits

Erdanat-4 may be prescribed for:

  • Urothelial carcinoma: Treatment of selected cases of bladder cancer.

  • FGFR-altered cancer: Used in patients whose tumours have specific susceptible FGFR2 or FGFR3 genetic alterations.

  • Targeted cancer treatment: Works by targeting molecular pathways involved in cancer cell growth.

  • Advanced cancer management: May be considered for eligible patients with locally advanced or metastatic disease following previous systemic treatment.

How Does Erdanat-4 Work?

Erdafitinib is a fibroblast growth factor receptor (FGFR) inhibitor. It blocks the activity of FGFR proteins, which can contribute to cancer cell growth, survival and multiplication.

By inhibiting these receptors, Erdafitinib helps interfere with signalling pathways that support the growth of certain FGFR-altered cancer cells.

Dosage and Directions for Use

  • Take Erdanat-4 only under the supervision of an oncologist.

  • The dose and treatment schedule must be determined by the treating specialist.

  • Swallow the tablet whole with water.

  • It may generally be taken with or without food.

  • Do not crush, chew or split tablets unless specifically instructed by your healthcare professional.

  • Do not change the dose or stop treatment without consulting your oncologist.

  • Regular blood tests and eye examinations may be required during treatment.

  • Follow your doctor's instructions if you miss a dose.

Possible Side Effects

Possible side effects include:

  • Increased phosphate levels in the blood (hyperphosphatemia)

  • Mouth sores or inflammation

  • Dry mouth

  • Diarrhoea

  • Nausea

  • Dry skin

  • Changes in nails

  • Reduced appetite

  • Taste changes

  • Fatigue

  • Changes in vision

Some patients may develop serious eye-related complications, including central serous retinopathy or retinal pigment epithelial detachment. Report blurred vision, visual disturbances or other eye symptoms to your oncologist immediately.

Precautions and Warnings

  • Erdanat-4 is a prescription anticancer medicine and must be used under specialist supervision.

  • Confirm the presence of the relevant FGFR genetic alteration before treatment.

  • Regular monitoring of blood phosphate levels is important.

  • Eye examinations should be performed before and during treatment as recommended by the oncologist.

  • Inform your doctor about kidney problems, liver conditions and existing eye disorders.

  • Tell your healthcare professional about all medicines, supplements and vitamins you take.

  • Erdafitinib may cause harm to an unborn baby. Effective contraception should be discussed with your doctor during treatment and for the recommended period afterwards.

  • Breastfeeding should be avoided during treatment and for the recommended period after the final dose.

  • Do not share this medicine with another person.

  • Store according to the manufacturer's packaging instructions and keep out of reach of children.

Frequently Asked Questions

1. What is Erdanat-4 4 mg used for?

It is used to treat eligible patients with certain FGFR-altered locally advanced or metastatic urothelial carcinoma.

2. What is the active ingredient in Erdanat-4?

It contains Erdafitinib 4 mg.

3. Is Erdanat-4 a chemotherapy medicine?

It is a targeted anticancer therapy rather than conventional chemotherapy. It works by inhibiting FGFR signalling pathways involved in certain cancer cells.

4. Which cancer is treated with Erdafitinib?

Erdafitinib is used for selected cases of urothelial carcinoma, particularly bladder cancer with susceptible FGFR2 or FGFR3 genetic alterations.

5. Does Erdanat-4 require genetic testing?

Yes. Testing for relevant FGFR genetic alterations is important to determine whether a patient may be eligible for treatment.

6. What is the pack size of Erdanat-4?

The supplied product packaging shows a bottle containing 28 tablets.

7. Who manufactures Erdanat-4?

Erdanat-4 is manufactured by Natco Pharma.

Contact us

For product enquiries and availability, contact India Medicine Seller.

Website: https://www.indiamedicineseller.com/

Email: support@indiamedicineseller.com

Conclusion

Erdanat-4 4 mg contains Erdafitinib, a targeted FGFR inhibitor used for selected patients with FGFR-altered advanced urothelial carcinoma. It works by blocking cancer-related FGFR signalling pathways. Treatment requires specialist supervision, genetic testing and regular monitoring throughout therapy.

 2026-11-06T10:23:23

Other Pages

View all pages